



## Essentials of Pharmaceutics

Edited by Linda A. Felton, PhD  
Chair, Department of Pharmaceutical Sciences  
Associate Professor of Pharmaceutics  
College of Pharmacy  
University of New Mexico  
Albuquerque, NM, USA



University of the Sciences  
Philadelphia  
College of  
Pharmacy



**Published by Pharmaceutical Press**

1 Lambeth High Street, London SE1 7JN, UK

© Pharmaceutical Press 2012

 is a trade mark of Pharmaceutical Press

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society

First edition published 2013

Typeset by Newgen KnowledgeWorks, India

Printed in the United States of America by Edwards Brothers Malloy

ISBN 978 0 85711 105 0

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder.

The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made.

A catalogue record for this book is available from the British Library.

This book is adapted from contributions published in *Remington: The Science and Practice of Pharmacy* 22<sup>nd</sup> edition.

# Contents

<b>Preface v</b>			
<b>About the editor vii</b>			
<b>Contributors ix</b>			
<b>Chapter 1</b>	Information resources in pharmacy and the pharmaceutical sciences <i>Robin H. Bogner, PhD and Sharon Giovenale, MSLS</i>	1	
<b>Chapter 2</b>	Analysis of medicinals <i>Raymond D. Skwierczynski, PhD</i>	9	
<b>Chapter 3</b>	Quality assurance and control <i>John H. Parker, PhD and John E. Enders, PhD, MBA</i>	29	
<b>Chapter 4</b>	Stability of pharmaceutical products <i>Allan D. Bokser, PhD and Patrick B. O'Donnell, PhD</i>	37	
<b>Chapter 5</b>	Bioavailability and bioequivalence <i>Steven B. Johnson, PharmD</i>	51	
<b>Chapter 6</b>	Dissolution <i>Vijai Kumar, MS, MBA and Praveen Hiremath, PhD</i>	63	
<b>Chapter 7</b>	Modern-day drug discovery and development <i>Rick G. Schnatz, PharmD</i>	81	
<b>Chapter 8</b>	The New Drug Approval Process <i>Linda A. Felton, PhD and Dennis W. Raisch, PhD, RPh</i>	93	
<b>Chapter 9</b>	Metrology and pharmaceutical calculations <i>Roger L. Schnaare, PhD and Shelly J. Prince, PhD</i>	101	
<b>Chapter 10</b>	Statistics <i>Sanford Bolton, PhD and Richard Hirsch, PhD</i>	133	
<b>Chapter 11</b>	Molecular structure, properties and states of matter <i>Thomas Rades, PhD, Keith C. Gordon, PhD and Kirsten Graeser, PhD</i>	177	
<b>Chapter 12</b>	Thermodynamics <i>Timothy S. Wiedmann, PhD</i>	207	
<b>Chapter 13</b>	Solutions and phase equilibria <i>Pardeep K. Gupta, PhD</i>	219	
<b>Chapter 14</b>	Separation methods <i>Loyd V. Allen, Jr., PhD, RPh</i>	241	
<b>Chapter 15</b>	Ionic solutions and electrolytic equilibria <i>Barbara R. Conway, PhD</i>	257	
<b>Chapter 16</b>	Tonicity, osmoticity, osmolality, osmolarity <i>Andrew Ingham, MRPharmS, PhD and Cathy Y. Poon, PharmD</i>	277	
<b>Chapter 17</b>	Chemical kinetics <i>Rodney J. Wigent, PhD</i>	301	
<b>Chapter 18</b>	Complex formation <i>Thorsteinn Loftsson, MSPHarm, MSc, PhD and Marcus E. Brewster, PhD</i>	317	
<b>Chapter 19</b>	Interfacial phenomena <i>Paul M. Bummer, PhD and Yvonne Perrie, PhD</i>	329	
<b>Chapter 20</b>	Colloidal dispersions <i>Bill J. Bowman, RPh, PhD, Clyde M. Ofner III, PhD, Hans Schott, PhD and Yvonne Perrie, PhD</i>	343	
<b>Chapter 21</b>	Coarse dispersions <i>James Swarbrick, DSc, PhD, Joseph T. Rubino, PhD, RPh and Orapin P. Rubino, PhD</i>	371	
<b>Chapter 22</b>	Rheology <i>Lawrence H. Block, PhD</i>	393	
<b>Chapter 23</b>	Powders <i>Yi-Bo Wang and Robert O. Williams III, PhD</i>	411	
<b>Chapter 24</b>	Solutions, Emulsions, Suspensions, and Extracts <i>Michael M. Crowley, PhD</i>	435	
<b>Chapter 25</b>	Sterilization Processes and Sterility Assurance <i>James Agalloco, BEChE, MSChE, MBA, William G. Lindboem, Jr., PhD and Russell E. Madsen, MS</i>	469	
<b>Chapter 26</b>	Parenteral Preparations <i>Michael J. Akers, PhD</i>	495	
<b>Chapter 27</b>	Pharmaceutical Compounding – USP <797> Sterile Preparations <i>Catherine Cone, PharmD, BCPS, Linda A. Felton, PhD, Amy Bachyrycz, PharmD</i>	533	
<b>Chapter 28</b>	Ophthalmic Preparations <i>Masood Chowhan, PhD, John C. Lang, PhD, Paul Missel, PhD</i>	541	
<b>Chapter 29</b>	Medicated Topicals <i>Lawrence H. Block, PhD</i>	565	
<b>Chapter 30</b>	Oral Solid Dosage Forms <i>Ahmed Adel Sakr, PhD and Fars K. Alanazi, PhD</i>	581	

vi CONTENTS

<b>Chapter 31</b>	Coating of Pharmaceutical Dosage Forms <i>Stuart C. Porter, PhD</i>	611	<b>Chapter 36</b>	Pharmaceutical Excipients <i>William J. Reilly, Jr., MBA</i>	683
<b>Chapter 32</b>	Oral Modified-Release Drug Delivery Systems <i>Ali R. Rajabi-Siahboomi, PhD, Manish S. Rane, PhD and Linda A. Felton, PhD</i>	623	<b>Chapter 37</b>	Basic pharmacokinetics and pharmacodynamics <i>Raymond E. Galinsky, PharmD and Craig K. Svensson, PharmD, PhD</i>	705
<b>Chapter 33</b>	Aerosols <i>John J. Sciarra, PhD and Christopher J. Sciarra, BS, MS Industrial Pharmacy</i>	633	<b>Chapter 38</b>	Drug action and effect <i>Donald N. Franz, PhD</i>	727
<b>Chapter 34</b>	Biotechnology and Drugs <i>Ara H. DerMarderosian, PhD and Zhiyu Li, PhD</i>	651	<b>Chapter 39</b>	Drug absorption, distribution, metabolism and excretion <i>Michael R. Franklin, PhD</i>	739
<b>Chapter 35</b>	Pharmaceutical Packaging <i>C. Jeanne Taborsky, BSChem and Kathleen Deiss, RN</i>	667	<b>Chapter 40</b>	Pharmacokinetics/pharmacodynamics in drug development <i>George L. Drusano, MD</i>	755
			<b>Index</b>		763

# Stability of Pharmaceutical Products

Allan D. Bokser, PhD and Patrick B. O'Donnell, PhD

INTRODUCTION 37

REGULATORY REQUIREMENTS 38

PRODUCT STABILITY 39

PREDICTING SHELF LIFE 45

APPROXIMATIONS IN ASSESSING  
PRODUCT STABILITY 45

PHARMACEUTICAL CONTAINERS 47

CLOSURES 48

## INTRODUCTION

Stability of a pharmaceutical product may be defined as the capability of a particular formulation, in a specific container/closure system, to remain within its physical, chemical, microbiological, therapeutic, and toxicological specifications at a defined storage condition. Pharmaceutical products are expected to meet their specifications for identity, purity, quality, and strength throughout their defined storage period at specific storage conditions. Assurances that the packaged product will be stable for its anticipated shelf life must come from an accumulation of valid data on the drug in its commercial package. These stability data include selected parameters that, taken together, form the stability profile.

The stability of a pharmaceutical product is investigated throughout the various stages of the development process. The stability of a drug substance is first assessed in the preformulation stage. At this stage, pharmaceutical scientists determine the drug substance and its related salts stability/compatibility with various solvents, buffered solutions and excipients considered for formulation development. Suitable analytical methods must be employed in order to ensure the likelihood that this assessment will be successful. Optimization of a stable formulation of a pharmaceutical product is built (using statistical design) upon the information obtained from the preformulation stage and continues during the formulation development stages.

Typically, the first formulation development stage may be for preclinical studies or as late as the preparation of a "first in human" formulation which is often a non-elegant formulation optimized for short-term dose-ranging clinical studies. The second major formulation development stage occurs to support Phase II clinical studies (proof of concept phase). The pharmaceutical product developed at this stage is usually the prototype for the commercial product. Therefore, the pharmaceutical product will be formulated based in part on the stability information obtained from the previous formulations and must meet stability requirements for longer-term clinical studies. In the final formulation development state for Phase III clinical studies, the formulation must be truly representative of what the commercial pharmaceutical product will be in order to avoid delays in approval. In addition to building on the clinical requirements of the drug, the commercial pharmaceutical product must also incorporate the commercial or the final market image of the product, which includes the container closure system. The stability of this product must be demonstrated to the appropriate regulatory agencies in order to assign an expiration period and date for the product. This expiration period allows for the assignment of an expiration date based on the manufacture date of each lot of drug product.

Once a pharmaceutical product has gained regulatory approval and is marketed, the pharmacist must understand the proper storage and handling of the drug. In some cases, a pharmacist may need to prepare stable compounded preparations from this product.

Most drug products are not shipped directly from the manufacturer to a pharmacy. Typically, a drug product is shipped from a manufacturer to a distribution center. From the distribution center the drug product is then shipped to a wholesaler. From the wholesaler, the drug product may be shipped to the distribution center for a pharmacy chain or directly to the pharmacy. Finally, the drug product is dispensed by the pharmacy to the patient. Dispensing of the drug product may be at a hospital, a clinic, and a traditional "brick and mortar" pharmacy or from a mail-order pharmacy. Therefore, the stability typically must also assess the robustness of the drug product through its supply chain. It is not unusual for temperature excursions to occur during these transfers of control.

Inventory control, or holding, of each drug is important for a wholesaler or pharmacy. A drug must be within its expiration dating throughout its use by the patient. Solid oral dosages may be dispensed in the commercial packaging or in a pharmacy supplied container closure system. Most prescriptions are supplied to patients for up to 30 or 90 days by traditional and mail-order pharmacies, respectively. Inventory control of product by wholesalers and pharmacies must assess how much dating must remain on a product for it to be useful for its customer. This causes the actual holding of a product to be shorter than the expiration date. Under normal circumstances it is unusual for a pharmacy to accept any product with less than 6 month dating remaining on a product.

Much has been written about the development of a stable pharmaceutical product. Comprehensive treatments of all aspects of pharmaceutical product stability have been published by Connors *et al.*<sup>1</sup>, Carstensen<sup>2</sup> and more recently by Allen.<sup>3</sup> This chapter will outline the appropriate steps from preformulation to drug approval to assure that the pharmaceutical product developed is stable. Requirements for compounded products will also be discussed.

The United States Pharmacopeia (USP) General Chapter <1191><sup>4</sup> defines the stability of a pharmaceutical product as "extent to which a product retains, within specified limits, and throughout its period of storage and use (i.e., its shelf life), the same properties and characteristics that it possessed at the time of its manufacture." There are five types of stability that must be considered for each drug (Table 4-1).

The use of kinetic and predictive studies for establishing credible expiration dating for pharmaceutical products is now accepted worldwide. Scientifically designed studies using reliable, meaningful, and specific stability-indicating assays, appropriate statistical concepts, and a computer to analyze the resulting data are used to determine an accurate and realistic shelf life. In this way the maximum amount of valid information is obtained to establish a reliable, defensible expiration date for each formulation. The assigned expiration date is a direct application and interpretation of the knowledge gained from the stability study.

Although there are exceptions, 90% of labeled potency generally is recognized as the minimum acceptable potency

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.